This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Psychiatry  • Adverse Effects  • Alert me on articles by topic

Arch Intern Med. 2001;161:2501-2502.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome or hypersensitive syndrome has been associated with the use of aromatic anticonvulsants, sulfonamides, calcium channel blockers, allopurinol, ranitidine, and thalidomide. The clinical manifestations include a diffuse maculopapular rash, fever, multivisceral involvement, eosinophilia, atypical lymphocytosis, and abnormal liver function test results.¹

Nevirapine is a potent and selective noncompetitive inhibitor of the reverse transcriptase enzyme of human immunodeficiency virus (HIV) type 1, inhibiting reverse transcriptase by binding to tyrosine components of the enzyme, which are located near the catalytic site.² It was the first nonnucleoside reverse transcriptase inhibitor approved for clinical use in patients infected with HIV and is used in combination with other antiretroviral agents.^3-4

Two cases of DRESS syndrome induced by the use of zalcitabine⁵ have been reported, and 4 cases were associated with nevirapine therapy.^6-7 The following is a report of a new case of DRESS syndrome associated with nevirapine . . . [Full Text of this Article]

Report of a Case


Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Drug Rash With Eosinophilia and Systemic Symptoms Syndrome and Renal Toxicity With a Nevirapine-Containing Regimen in a Pregnant Patient With Human Immunodeficiency Virus
Knudtson et al.
Obstet Gynecol 2003;101:1094-1097.
ABSTRACT | FULL TEXT